Scisparc is a cutting-edge brand that specializes in developing therapeutics to mitigate adverse symptoms associated with central nervous system (CNS) disorders. They capitalize on the biochemistry of receptors that modulate the CNS to create innovative compounds that target the endocannabinoid system. Scisparc's pipeline consists of FDA-approved medications and New Chemical Entities (NCEs) that show strong potential in treating specific conditions where effective therapies are lacking.

By enhancing existing compounds with their proprietary technologies, Scisparc has developed novel therapies that exhibit heightened bioavailability, improved efficacy, lower dosage requirements, better safety profiles, and reduced side effects. Led by a skilled management team, including Amitay Weiss, the Chairman, and Oz Adler, the Chief Executive Officer and Chief Financial Officer, Scisparc combines expertise in finance, research and development, and technology to drive innovation in the healthcare industry. With a focus on the future and a dedication to improving the lives of patients, Scisparc is at the forefront of revolutionizing CNS disorder treatments.

Contact them today for more information